Search Results

REDUCE FMR Evaluates Cardiac Dimensions' Carillon Mitral Contour System

September 23, 2018—Cardiac Dimensions, Inc. announced that results of the company’s landmark REDUCE FMR clinical trial were presented by Professor Horst Sievert, MD, at TCT 2018, the 30th annual Transcatheter Cardiovascular Therapeutics scientific symposium held September 21–25 in San Diego, California.

First-in-Man Clinical Investigation Begins for the Carag Bioresorbable Septal Occluder

May 14, 2014—Carag AG announced the first-in-human use of the Carag bioresorbable septal occluder (CBSO), which was implanted in a clinical investigation led by Prof.

Coherex FlatStent Cleared in EU for PFO Closure

July 8, 2009—Coherex Medical, Inc. (Salt Lake City, UT) announced that the Coherex FlatStent EF patent foramen ovale (PFO) closure system has been granted CE Mark clearance for use in Europe and other countries.

Coherex FlatStent Cleared in EU for PFO Closure

July 8, 2009—Coherex Medical, Inc. (Salt Lake City, UT) announced that the Coherex FlatStent EF patent foramen ovale (PFO) closure system has been granted CE Mark clearance for use in Europe and other countries.

Carag Begins European Marketing After CE Mark Approval for Bioresorbable Septal Occluder  

September 18, 2017—Carag AG announced that it has received European CE Mark approval for its Carag bioresorbable septal occluder (CBSO), allowing Carag to fully market the CBSO in the European Union, Switzerland, and other countries.

European STRENGTH Trial Will Evaluate Long-Term Impact of RenalGuard Therapy in Patients at High Risk for CI-AKI

January 26, 2016—RenalGuard Solutions, Inc. announced that the STRENGTH trial will begin later this year.

Neurotronic’s Neuviant Multiorgan Denervation Studied to Treat Type 2 Diabetes and Hypertension 

November 17, 2025—Neurotronic, Inc. announced the first clinical outcomes of the NECTAR III and NECTAR IV trials evaluating the company’s Neuviant multiorgan denervation (MDN) system in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN).

REDUCE-HTN Data Support Boston Scientific's Vessix Renal Denervation System

October 28, 2013—Boston Scientific Corporation (Natick, MA) announced that new data presented at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California, demonstrated that patients treated with the company's Vessix renal denervation system experienced a significant and sustained reduction in blood pressure.

Venock Furthers Development of Automated Closure Device for Large Bore Venous Access Sites

July 21, 2021—Venock Inc. is developing a vascular closure system designed to close very large perforations that can be as big as the diameter of the operable vein or artery.

Interim Data From REDUCE-HTN Support Boston Scientific's Vessix Renal Denervation System

May 22, 2013—Boston Scientific Corporation (Natick, MA) announced that interim data from the REDUCE-HTN clinical program were presented at EuroPCR 2013 in Paris by Joachim Schofer, MD, of the Hamburg University Cardiovascular Center in Hamburg, Germany.

CE Mark Approved for Boston Scientific's Next-Generation Watchman FLX LAA Closure Device

November 19, 2015—Boston Scientific announced European CE Mark approval for the Watchman FLX left atrial appendage (LAA) closure device.

TruLeaf Medical’s RoseDoc TMVR Platform to Be Evaluated in First-in-Human Trial

February 1, 2023—AllMeD Solutions announced that the company’s subsidiary, TruLeaf Medical, has received the Helsinki Ethics Committee’s approval to conduct a first-in-human clinical trial of the TruLeaf RoseDoc transcatheter mitral valve replacement (TMVR) platform.

Vivasure Medical's PerQseal Large-Bore Closure Device Launched in Europe

November 9, 2018—Vivasure Medical Limited announced the commercial European launch of the company’s PerQseal large-bore closure device, a percutaneous vessel closure device designed for use in large-bore transcatheter procedures.

Boston Scientific Acquires Vessix Vascular

November 8, 2012—Boston Scientific Corporation (Natick, MA) has announced a definitive agreement to acquire Vessix Vascular, Inc. (Laguna Hills, CA), which developed a catheter-based renal denervation system for the treatment of uncontrolled hypertension.

Postmarket Study Begins for Medtronic's CoreValve

March 12, 2010—Medtronic, Inc. (Minneapolis, MN) announced that enrollment has commenced in Europe in the CoreValve Advance postmarket clinical study of the CoreValve transcatheter aortic valve system.

Medtronic Commences Postmarket Evaluation of CoreValve Aortic Valve System

March 12, 2010—Medtronic, Inc. (Minneapolis, MN) announced that enrollment has commenced in Europe in the CoreValve Advance postmarket clinical study of the CoreValve transcatheter aortic valve system.

Vectorious Begins VECTOR-HF FIH Trial to Support European Approval of V-LAP Device

February 4, 2019—Vectorious Medical Technologies Ltd. announced the initiation of the VECTOR-HF first-in-human (FIH) clinical trial.

Vascular Dynamics Receives Financing to Support Clinical Trials of MobiusHD Device for Heart Failure

July 12, 2022—Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on endovascular device-based solutions for heart failure, announced the closing of its $20 million financing round.